(Q38855286)

7 September 2017

title

In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs (English)

1 reference

7 September 2017

main subject

Cryptococcus neoformans

1 reference

1 reference

Hassan A Abdel-Salam

1

1 reference

7 September 2017

language of work or name

1 reference

1 September 2005

1 reference

7 September 2017

1 reference

7 September 2017

volume

48

1 reference

7 September 2017

issue

5

1 reference

7 September 2017

page(s)

327-332

1 reference

Effect of heat-treated amphotericin B on renal and fungal cytotoxicity

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Use of amphotericin B with azole antifungal drugs: what are we doing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1439-0507.2005.01137.X

10.1111/J.1439-0507.2005.01137.X

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference